Plancorp LLC trimmed its position in Pfizer, Inc. (NYSE:PFE) by 0.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,695 shares of the biopharmaceutical company’s stock after selling 331 shares during the quarter. Plancorp LLC’s holdings in Pfizer were worth $2,004,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in PFE. Fisher Asset Management LLC raised its stake in Pfizer by 3.9% in the second quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after purchasing an additional 1,275,832 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Pfizer by 1.2% in the first quarter. Schwab Charles Investment Management Inc. now owns 31,260,823 shares of the biopharmaceutical company’s stock valued at $1,069,433,000 after purchasing an additional 377,404 shares in the last quarter. Macquarie Group Ltd. raised its stake in Pfizer by 0.9% in the first quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock valued at $844,431,000 after purchasing an additional 228,405 shares in the last quarter. Boston Partners raised its stake in Pfizer by 7.3% in the first quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after purchasing an additional 1,649,801 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in Pfizer by 1.2% in the second quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock valued at $622,562,000 after purchasing an additional 227,682 shares in the last quarter. 69.00% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Pfizer, Inc. (PFE) traded down 0.28% on Thursday, hitting $35.86. 5,727,027 shares of the stock traded hands. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $36.24. The firm has a 50 day moving average price of $34.55 and a 200 day moving average price of $33.66. The firm has a market cap of $213.27 billion, a PE ratio of 26.23 and a beta of 1.00. Pfizer also saw some unusual options trading on Monday. Stock traders acquired 24,211 call options on the stock. This represents an increase of approximately 129% compared to the typical daily volume of 10,577 call options.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the prior year, the firm posted $0.64 EPS. Pfizer’s quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be issued a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.56%. Pfizer’s payout ratio is presently 94.12%.

A number of brokerages recently weighed in on PFE. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Tuesday. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, September 19th. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $35.00 to $39.00 in a research note on Wednesday, September 20th. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a research note on Wednesday, September 13th. Finally, Jefferies Group LLC set a $37.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research note on Monday, September 18th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $38.21.

COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/pfizer-inc-pfe-stake-lessened-by-plancorp-llc.html.

In related news, insider Sally Susman sold 38,230 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares in the company, valued at approximately $5,097,715. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ian C. Read sold 96,950 shares of the stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Insiders have sold a total of 464,521 shares of company stock worth $15,813,961 in the last 90 days. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.